3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
2
Stomach Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Bile Duct Neoplasms
1
Advanced Non-Small Cell Lung Cancer
1
Adenocarcinoma Of Esophagus
1
Interventions
Fluorouracil
16
Oxaliplatin
14
Nivolumab
14
Leucovorin
13
pembrolizumab
9
Paclitaxel
9
Capecitabine
9
Radiotherapy
6
Radiation
6
durvalumab
5
Taxes
5
Irinotecan
5
Cisplatin
5
Trastuzumab
4
Specimen Handling
4
Drug Therapy
4
Carboplatin
4
tremelimumab
3
dehydroftorafur
3
Ramucirumab
3
Magnetic Resonance Spectroscopy
3
Folfox protocol
3
Endoscopy
3
Docetaxel
3
Biopsy
3
zimberelimab
2
zanidatamab
2
trastuzumab deruxtecan
2
tislelizumab
2
futibatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma Of Esophagus
×
quemliclustat
×
1 year
×
Clear all
NCT05329766
2026-06-02
EDGE-Gastric
Arcus Biosciences, Inc.
Phase 2
Active not recruiting
332 enrolled